CLOs on the Move

MYM Nutraceuticals

www.mym.ca

 
MYM Nutraceuticals Inc. (CSC:MYM) (OTC:MYMMF) (FRA:OMY) is an emerging bio-pharmaceutical company and distributor of medical marijuana products that has applied to Health Canada for a medical marijuana production and distribution license under the Marihuana for Medical Purposes Regulations. MYM Nutraceuticals has an extensive list of industry assets that make it well prepared for commercial distribution of medical marijuana, including a growing facility property, exclusive access to patients and many years of industry expertise on the company`s board of directors and staff.
  • Number of Employees: 25-100
  • Annual Revenue: $100-250 Million
  • www.mym.ca
  • 1095 W Pender Street Suite 250
    Vancouver, BC CAN V6E 2M6
  • Phone: 778.522.2261

Executives

Name Title Contact Details

Similar Companies

EntreMed

EntreMed is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioAgilytix

BioAgilytix is a leading bioanalytical contract research organization (CRO) that supports the development of novel therapeutic biologics and biosimilars. Located in Research Triangle Park, North Carolina, BioAgilytix specializes in large-molecule bioanalysis providing critical insight into the safety, efficacy, and mechanism of action of drug candidates throughout the clinical trial process. Specifically, BioAgilytix offers assay development, validation, and sample analysis services for immunoassays and cell-based assays under non-GLP, spirit-of-GLP, and GLP, as well as product release testing under GMP. BioAgilytix is an engaged and energetic partner committed to delivering exceptional value and veteran expertise through a collaborative process that consistently results in successful projects.

KaVo Dental Corporation

KaVo Dental Corporation is a Charlotte, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nuvelo

Nuvelo, Inc. is a San Carlos, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

QurAlis

QurAlis is developing precision therapeutics for ALS, a terminal disease that causes muscle paralysis through degeneration of the motor system. We are digging deep into the root causes of the multiple sub-forms of this destructive disease and focus our programs on tackling specific disease-causing mechanisms.